These drugmaker stocks may have been hammered down to bargain-bin prices.
Compare SRRK Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Scholar Rock Holding Corp
News & Analysis: Scholar Rock Holding Corp
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
Investors are fired up about the company's interim phase 2 results for an experimental spinal muscular atrophy drug.
Find out why these stocks missed the rally.
The good news? The cause of the drop should be a temporary issue.
Several stocks simply lost momentum from past successes.